Alto Neuroscience, Inc.

NYSE:ANRO Stock Report

Market Cap: US$753.5m

Alto Neuroscience Future Growth

Future criteria checks 0/6

Alto Neuroscience's earnings are forecast to decline at 1.9% per annum while its annual revenue is expected to grow at 73.7% per year. EPS is expected to grow by 5.9% per annum.

Key information

-1.9%

Earnings growth rate

5.94%

EPS growth rate

Pharmaceuticals earnings growth14.7%
Revenue growth rate73.7%
Future return on equityn/a
Analyst coverage

Good

Last updated04 Jun 2026

Recent future growth updates

Recent updates

Analysis Article • Jan 01

Alto Neuroscience, Inc.'s (NYSE:ANRO) Intrinsic Value Is Potentially 33% Above Its Share Price

Key Insights Using the 2 Stage Free Cash Flow to Equity, Alto Neuroscience fair value estimate is US$23.71 Alto...
Analysis Article • Nov 22

Alto Neuroscience (NYSE:ANRO) Has Debt But No Earnings; Should You Worry?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
Seeking Alpha • Mar 21

Alto Neuroscience: Potential First-In-Class Approach To Targeting CNS Disorders

Summary Results from phase 2b study, using ALTO-100 for the treatment of patients with Major Depressive Disorder, expected in the 2nd half of 2024. Results from phase 2b study, using ALTO-300 for the treatment of patients with Major Depressive Disorder, expected in the 1st half of 2025. The major depressive disorder market across the 8 major markets is expected to grow to $9.6 billion in 2029. The Precision Psychiatry Platform is designed to help the company develop drugs where patients are likely to respond to treatment based on biomarker confirmation. Read the full article on Seeking Alpha

Earnings and Revenue Growth Forecasts

NYSE:ANRO - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20283-153-170-1467
12/31/2027N/A-132-141-12610
12/31/2026N/A-104-94-9711
3/31/2026N/A-74-63-62N/A
12/31/2025N/A-63-52-52N/A
9/30/2025N/A-62-54-53N/A
6/30/2025N/A-65-57-55N/A
3/31/2025N/A-63-55-53N/A
12/31/2024N/A-61-49-47N/A
9/30/2024N/A-57-48-46N/A
6/30/2024N/A-50-43-42N/A
3/31/2024N/A-42-38-37N/A
12/31/2023N/A-36-34-33N/A
9/30/2023N/A-33-28-28N/A
12/31/2022N/A-28-21-20N/A
12/31/20210-9-10-9N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ANRO is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ANRO is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ANRO is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ANRO is forecast to have no revenue next year.

High Growth Revenue: ANRO is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if ANRO's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/14 13:14
End of Day Share Price 2026/06/12 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Alto Neuroscience, Inc. is covered by 13 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Brian SkorneyBaird
Tazeen AhmadBofA Global Research
Thomas ShraderBTIG